Desmetramadol featured today in new article by Research Outreach

Related Articles

News
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer
- by Syntrix
News
Syntrix featured in the NIH Innovation Zone at 2014 Bio International Convention in San Diego, CA
- by Syntrix
News
Syntrix Receives $2.3M Grant to Conduct a Phase 1/2 Clinical Trial Evaluating SX-682 Alone and with Pembrolizumab in Metastatic Melanoma
- by Syntrix
Bitnami